Ethical Dilemmas - Advanced: Worksheet 2 - Beginner Practice Ethical Dilemmas - Advanced BEGINNER

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.

Action I creates responsible use framework before deployment. Action II ensures ongoing accountability and prevents misuse. Action III applies risk-based approach to client selection. Action IV is too broad - legitimate law enforcement uses exist; blanket bans prevent beneficial applications. Action V ignores ethical responsibility - 'technology neutrality' argument doesn't absolve creators of misuse consequences. Technology Ethics Framework: Responsible innovation (I) + Accountability (II) + Risk assessment (III) vs. Blanket prohibition (IV) or No responsibility (V). Dual-Use Technology Principle: Technologies with both beneficial and harmful potential require governance, not blanket bans or unrestricted access. Corporate Responsibility Spectrum: I, II, III (Balanced ethical approach), IV (Overly restrictive), V (Abdicating responsibility). Legal-Ethical Analysis: Companies have moral and legal duty to consider foreseeable harm; I, II, III fulfill this duty while preserving legitimate uses.

Action I balances commercial viability with social responsibility through differential pricing. Action II shares burden with public sector for social welfare. Action III maintains company's IP rights while expanding access through controlled licensing. Action IV completely disregards IP rights and removes incentive for innovation - it's legally problematic and discourages future R&D investment. Action V ignores humanitarian aspect entirely. Ethical Business Framework: Commercial sustainability + Social responsibility (I, II, III) vs. Pure profit motive (V) or IP rights violation (IV). Stakeholder Analysis: I (Balances patients, company, shareholders), II (Involves government responsibility), III (Balances access and IP rights), IV (Benefits patients but harms innovation ecosystem), V (Benefits shareholders only). Long-term Perspective: I, II, III create sustainable model for current and future drug development; IV discourages future innovation; V creates access crisis.